Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHA-739358 in metastatic hormone-refractory prostate cancer
2006-006136-21Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of danusertib in prostate cancer (PCa) (2 arms), sponsored by Nerviano Medical Sciences. Primary endpoint: PSA response rate within first three months. Started Jul 2007; status: completed.
02
Drugs
danusertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-006136-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006136-21.